Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Dasatinib in CML
NCT03216070Phase 4Unknown
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Apr 2016
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03216070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216070.